GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Financial Strength

PRME (Prime Medicine) Financial Strength : 4 (As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Financial Strength?

Prime Medicine has the Financial Strength Rank of 4.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

GuruFocus does not calculate Prime Medicine's interest coverage with the available data. Prime Medicine's debt to revenue ratio for the quarter that ended in Sep. 2024 was 49.34. As of today, Prime Medicine's Altman Z-Score is -2.48.


Competitive Comparison of Prime Medicine's Financial Strength

For the Biotechnology subindustry, Prime Medicine's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Prime Medicine's Financial Strength Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Prime Medicine's Financial Strength distribution charts can be found below:

* The bar in red indicates where Prime Medicine's Financial Strength falls into.



Prime Medicine Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Prime Medicine's Interest Expense for the months ended in Sep. 2024 was $0.00 Mil. Its Operating Income for the months ended in Sep. 2024 was $-54.23 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $36.76 Mil.

Prime Medicine's Interest Coverage for the quarter that ended in Sep. 2024 is

GuruFocus does not calculate Prime Medicine's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Prime Medicine Inc has enough cash to cover all of its debt. Its financial situation is stable.

2. Debt to revenue ratio. The lower, the better.

Prime Medicine's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Sep. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(4.484 + 36.764) / 0.836
=49.34

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Prime Medicine has a Z-score of -2.48, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -2.48 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Prime Medicine  (NAS:PRME) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Prime Medicine has the Financial Strength Rank of 4.


Prime Medicine Financial Strength Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Prime Medicine Business Description

Traded in Other Exchanges
N/A
Address
21 Erie Street, Cambridge, MA, USA, 02139
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Executives
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Alphabet Inc. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson officer: See Remarks 88 SIDNEY STREET, CAMBRIDGE MA 02139
Meredith Goldwasser officer: SVP, Strategy & Corporate Ops. PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Jeremy Duffield officer: Chief Scientific Officer PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139